Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs.
CONCLUSION: RA Medicare Fee-For-Service beneficiaries who either switch or initiated abatacept have a lower infection-related hospitalization risk and cost compared to patients who switched to or initiated other tDMARDs.
PMID: 33502940 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Abatacept | Arthritis | Economics | Health Management | Medicare | Orencia | Pneumonia | Respiratory Medicine | Rheumatoid Arthritis | Rheumatology | Skin | Study